TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33653216

Group type: EXPERIMENTAL
Intervention: Induction with fludarabine, cyclophosphamide, and ofatumumab; consolidation with 4 doses of ofatumumab for MRD+ patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention for MRD- patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall treatment (including induction and consolidation)
Number of subjects: 28
Study: 33653294

Group type: EXPERIMENTAL
Intervention: Standard practice treatment according to the center
Number of subjects: 6000
Study: 33653374

Group type: EXPERIMENTAL
Intervention: CPS-mandated treatment
Number of subjects: 245

Group type: COMPARATOR
Intervention: Stress score increase
Number of subjects: 245

Group type: COMPARATOR
Intervention: Co-occurring mental health diagnosis
Number of subjects: 245
Study: 33653394

Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 16
Study: 33653910

Group type: EXPERIMENTAL
Intervention: Very elderly subjects (age ≥ 80 years)
Number of subjects: 5557

Group type: COMPARATOR
Intervention: Elderly subjects (age < 80 years)
Number of subjects: 5557

Group type: EXPERIMENTAL
Intervention: Age as a risk factor
Number of subjects: 5557
Study: 33654016

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 33654090

Group type: EXPERIMENTAL
Intervention: BBV152 vaccine candidate (three different formulations) administered at 0 and 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33654117

Group type: EXPERIMENTAL
Intervention: Human intravital microscopy (HIVM)
Number of subjects: 30
Study: 33654213

Group type: EXPERIMENTAL
Intervention: Circulating CD103
Number of subjects: 0
Study: 33654407

Group type: EXPERIMENTAL
Intervention: TEAM intervention (curriculum-guided self-management approach using peer dyads)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 160
Study: 33654425

Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lidocaine patch 5%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lidocaine medicated plaster 5%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Generic lidocaine patch 5%
Number of subjects: 125
Study: 33655197

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate heptahydrate (FeSO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33655364

Group type: EXPERIMENTAL
Intervention: PTFE grafts during pancreatectomy
Number of subjects: 19
Study: 33655413

Group type: EXPERIMENTAL
Intervention: Everion® wearable device (WD) for 14 days
Number of subjects: 20
Study: 33655551

Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 112

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 112
Study: 33655675

Group type: EXPERIMENTAL
Intervention: Calcium alginate hydrogel sealant
Number of subjects: 20
Study: 33655723

Group type: EXPERIMENTAL
Intervention: AHREs >6 minutes
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: LA diameter >41 mm
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Sick sinus syndrome
Number of subjects: 816
Study: 33655941

Group type: EXPERIMENTAL
Intervention: Adipose tissue MSC obtained by enzymatic method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanically fragmented adipose tissue
Number of subjects: 100
Study: 33655955

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA1 group, CDE < 3 cm)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA2 group, 3 cm ≤ CDE < 6 cm)
Number of subjects: 400
Study: 33655971

Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection (ILESI)
Number of subjects: 65
Study: 33655979

Group type: EXPERIMENTAL
Intervention: Automatic tongue diagnosis system (ATDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy group (control)
Number of subjects: 0
Study: 33656448

Group type: EXPERIMENTAL
Intervention: FASST intervention (n=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (basic app with educational resources; n=10)
Number of subjects: 30
Study: 33656471

Group type: EXPERIMENTAL
Intervention: Self-reported psychiatric history
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Concussion diagnosis
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: History of previous concussion
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Interval from injury to ED presentation
Number of subjects: 272
Study: 33656536

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical TCRαβ+/CD19+ cell-depleted hematopoietic stem cell transplantation (HSCT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical TCRαβ+/CD19+ cell-depleted HSCT
Number of subjects: 24
Study: 33656739

Group type: EXPERIMENTAL
Intervention: Peficitinib 50 or 100 mg/day (with dose adjustments allowed)
Number of subjects: 843
Study: 33657038

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin for chemoprevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality indicators for colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organized CRC screening approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive screening tests to diagnostic colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effective, highly accurate, noninvasive modalities
Number of subjects: 0
Study: 33657112

Group type: EXPERIMENTAL
Intervention: ZIKV non-infected women
Number of subjects: 731

Group type: COMPARATOR
Intervention: ZIKV-exposed infants
Number of subjects: 731
Study: 33657208

Group type: EXPERIMENTAL
Intervention: Long-stored RBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion through human spleen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusion of long-stored RBCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macrophage-depleted mice
Number of subjects: 0
Study: 33657217

Group type: EXPERIMENTAL
Intervention: Reinforcement learning (RL) algorithm for increasing physical activity
Number of subjects: 0
Study: 33657398

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: CMR
Number of subjects: 50
Study: 33657594

Group type: EXPERIMENTAL
Intervention: Use of AxiSanté 5-Infansoft software for electronic medical records by pediatricians trained in infectious diseases.
Number of subjects: 57806

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test for tonsillopharyngitis.
Number of subjects: 57806

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment following French guidelines, specifically amoxicillin.
Number of subjects: 57806
Study: 33657782

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) (22 gauge)
Number of subjects: 48

Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (EUS-FNA) (25 gauge)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both EUS-FNB and EUS-FNA
Number of subjects: 48
Study: 33657786

Group type: EXPERIMENTAL
Intervention: Daratumumab + bortezomib/thalidomide/dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33657839

Group type: EXPERIMENTAL
Intervention: Peer-Led Group Lifestyle Balance (PGLB) intervention
Number of subjects: 63
Study: 33657843

Group type: EXPERIMENTAL
Intervention: Peer-delivered healthy lifestyle intervention
Number of subjects: 0
Study: 33657859

Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Both antithrombotics and statins
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Anticoagulation for atrial fibrillation
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Controlled hypertension
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Controlled dyslipidemia
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Controlled diabetes
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Uncontrolled diabetes
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Uncontrolled dyslipidemia
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Decreased use of statins
Number of subjects: 404
Study: 33657991

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33658034

Group type: EXPERIMENTAL
Intervention: Lactation support program (in-home lactation consultant visits, breast pumps)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Lactation support program
Number of subjects: 199

Group type: COMPARATOR
Intervention: Maternal sociodemographics and food insecurity
Number of subjects: 199
Study: 33658052

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) 0.10 mg/kg, 0.15 mg/kg, and 0.20 mg/kg IV infusions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 11
Study: 33658056

Group type: EXPERIMENTAL
Intervention: In-scanner exercise stress cardiovascular magnetic resonance (ExCMR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiparametric approach using ExCMR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 60
Study: 33658080

Group type: EXPERIMENTAL
Intervention: Q-CAN®
Number of subjects: 19
Study: 33658305

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study: 33658610

Group type: EXPERIMENTAL
Intervention: Wearable sensors for measuring total sleep opportunity (TSO) and total sleep time (TST)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wearable sensors for measuring total scratching duration
Number of subjects: 32
Study: 33658752

Group type: EXPERIMENTAL
Intervention: Phacoemulsification procedures
Number of subjects: 200
Study: 33658841

Group type: EXPERIMENTAL
Intervention: Pregabalin (300-450 mg/day)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 33658915

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) training for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Baseline integrity of three target white matter tract groups
Number of subjects: 38
Study: 33658980

Group type: EXPERIMENTAL
Intervention: Glucose challenge during OGTT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no family history of diabetes)
Number of subjects: 24
Study: 33658994

Group type: EXPERIMENTAL
Intervention: Genetically modified immune cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33659204

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Apatinib 425 mg once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Apatinib and etoposide
Number of subjects: 31
Study: 33659227

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33659261

Group type: EXPERIMENTAL
Intervention: Empirical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided therapy
Number of subjects: 0
Study: 33659267

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 33660142

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimodality therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33660194

Group type: EXPERIMENTAL
Intervention: LY3023414 200 mg BID
Number of subjects: 42
Study: 33660197

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 3437

Group type: EXPERIMENTAL
Intervention: 2-h Postprandial Blood Glucose (2hPG)
Number of subjects: 3437

Group type: COMPARATOR
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 3437
Study: 33660198

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg/flexibly dosed
Number of subjects: 2836

Group type: COMPARATOR
Intervention: Comparator (placebo, sitagliptin 100 mg, or liraglutide 1.8 mg)
Number of subjects: 2836
Study: 33660230

Group type: EXPERIMENTAL
Intervention: Apixaban Prescriber Guide
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Apixaban Patient Alert Card
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Overall knowledge of bleeding risk among HCPs and patients
Number of subjects: 510
Study: 33660625

Group type: EXPERIMENTAL
Intervention: Cannabis use (specific cannabinoids not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33660690

Group type: EXPERIMENTAL
Intervention: 99mTc-WBC-SPECT/CT with conventional visual assessment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 99mTc-WBC-SPECT/CT with semi-quantitative scoring system (CSI)
Number of subjects: 68
Study: 33660691

Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose-PET (18F-FDG-PET) scanning
Number of subjects: 64
Study: 33661054

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33661120

Group type: EXPERIMENTAL
Intervention: Proprietary synbiotic medical food
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 33661130

Group type: EXPERIMENTAL
Intervention: Manage My Pain app (MMP) used alongside standard care
Number of subjects: 246

Group type: COMPARATOR
Intervention: Data entered on paper-based questionnaires (nonapp group)
Number of subjects: 246
Study: 33661190

Group type: EXPERIMENTAL
Intervention: Ibrutinib, 840 mg PO QD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 18
Study: 33661274

Group type: EXPERIMENTAL
Intervention: High levels of circulating cell-free mitochondrial DNA (cf-mtDNA) in patients with SCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA in patient samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient plasma containing high levels of cf-mtDNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of TANK-binding kinase 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating SCD red blood cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cf-mtDNA
Number of subjects: 0
Study: 33661297

Group type: EXPERIMENTAL
Intervention: Magnetic resonance direct thrombus imaging (MRDTI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Compression ultrasonography (CUS) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CUS followed by MRDTI in case of inconclusive CUS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Strategies without MRDTI
Number of subjects: 10
Study: 33661301

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel + carboplatin) plus nivolumab for 3 cycles followed by adjuvant nivolumab for 1 year
Number of subjects: 46
Study: 33661521

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 5136
Study: 33661539

Group type: EXPERIMENTAL
Intervention: Antistaphylococcal cephalosporins
Number of subjects: 8073

Group type: EXPERIMENTAL
Intervention: Broad spectrum penicillins plus betalactamase inhibitors
Number of subjects: 8073

Group type: COMPARATOR
Intervention: Systemic antibiotics
Number of subjects: 8073

Group type: COMPARATOR
Intervention: Lavage
Number of subjects: 8073
Study: 33662164

Group type: EXPERIMENTAL
Intervention: AIPS-E
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: IPS-E
Number of subjects: 292
Study: 33662447

Group type: EXPERIMENTAL
Intervention: Risk-stratified treatments based on disease biomarkers
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Next generation sequencing on bulk tumors
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Single-cell sequencing approaches
Number of subjects: 350
Study: 33662597

Group type: EXPERIMENTAL
Intervention: Physical activity (measured by accelerometer: steps, time in any/moderate-to-vigorous/vigorous physical activity, intensity and sedentary time)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Heart rate recovery (HRR) and chronotropic response (CR) measured during a 6-min walk test (6MWT)
Number of subjects: 320
Study: 33662654

Group type: EXPERIMENTAL
Intervention: Containment and mitigation measures (lockdown)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Risk and protective factors
Number of subjects: 239

Group type: COMPARATOR
Intervention: Living conditions
Number of subjects: 239
Study: 33663038

Group type: EXPERIMENTAL
Intervention: Pain extent
Number of subjects: 190
Study: 33663084

Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: no ATG
Number of subjects: 72
Study: 33663395

Group type: EXPERIMENTAL
Intervention: Educational program for ambulance telecommunicators (20-min theory-based educational video)
Number of subjects: 0
Study: 33663430

Group type: EXPERIMENTAL
Intervention: Robust group
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Pre-frail group
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Frail group
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 625
Study: 33663527

Group type: EXPERIMENTAL
Intervention: PedsQL™ 4.0 generic health-related quality of life questionnaire
Number of subjects: 123
Study: 33663560

Group type: EXPERIMENTAL
Intervention: Lapatinib plus veliparib
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 33663620

Group type: EXPERIMENTAL
Intervention: CUSP implementation strategy including provider training, expert facilitation, and a five-step quality improvement process.
Number of subjects: 0
Study: 33663745

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology 0/1-h Algorithms
Number of subjects: 0
Study: 33663941

Group type: EXPERIMENTAL
Intervention: Neratinib at 240 mg daily in 28-day cycles
Number of subjects: 25
Study: 33664072

Group type: EXPERIMENTAL
Intervention: In-Motion-App for remote General Movement Assessment (GMA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 7-point body tracker software
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Instructions for filming
Number of subjects: 86
Study: 33664128

Group type: EXPERIMENTAL
Intervention: hu3S193, 30 mg/m² intravenous infusions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 29
Study: 33664279

Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies
Number of subjects: 12928
Study: 33664689

Group type: EXPERIMENTAL
Intervention: Physical frailty (mobility frailty) or robust
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Reversible cognitive frailty (RCF) and non-mobility RCF
Number of subjects: 429

Group type: COMPARATOR
Intervention: Cognitive decline (CF)
Number of subjects: 429
Study: 33665371

Group type: EXPERIMENTAL
Intervention: Reverse transcription-PCR testing
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Serology testing
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Contact with a person with confirmed COVID-19
Number of subjects: 605
Study: 33665468

Group type: EXPERIMENTAL
Intervention: Building Resilience for Healthy Kids (Healthy Kids) program
Number of subjects: 0
Study: 33665614

Group type: EXPERIMENTAL
Intervention: Brief vigorous stair climbing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33665745

Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 16
Study: 33666177

Group type: EXPERIMENTAL
Intervention: PwO
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: HCPs
Number of subjects: 1000
Study: 33666246

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 3051

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3051
Study: 33666272

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33666562

Group type: EXPERIMENTAL
Intervention: HeartMan system (mobile app connected to a wristband and cloud services)
Number of subjects: 56
Study: 33666654

Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 106/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 107/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: iTregs at 3.0 × 108/kg with CSA/MMF
Number of subjects: 14

Group type: COMPARATOR
Intervention: iTregs at 3.0 × 108/kg with sirolimus/MMF
Number of subjects: 14
Study: 33666880

Group type: EXPERIMENTAL
Intervention: Baseline physical performance (SPPB score)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Baseline physical performance (HGS)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Baseline GDS score
Number of subjects: 1679
Study: 33667180

Group type: EXPERIMENTAL
Intervention: > 0 to < 1 drinks/d
Number of subjects: 3852

Group type: EXPERIMENTAL
Intervention: 1 to < 2 drinks/d
Number of subjects: 3852

Group type: EXPERIMENTAL
Intervention: ≥ 2 drinks/d
Number of subjects: 3852

Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 3852
Study: 33667197

Group type: EXPERIMENTAL
Intervention: Grade 2 rejection
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Grade 3 rejection
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: VCA rejection
Number of subjects: 7

Group type: COMPARATOR
Intervention: Grade 1 rejection
Number of subjects: 7
Study: 33667672

Group type: EXPERIMENTAL
Intervention: Multilevel smoothing splines (MSS) for capturing nonlinearity in quantitative predictors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSS modeling approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3dMSS program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal dataset of structural MRI scans
Number of subjects: 0
Study: 33668011

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 6857

Group type: EXPERIMENTAL
Intervention: Mild smokers
Number of subjects: 6857

Group type: EXPERIMENTAL
Intervention: Moderate smokers
Number of subjects: 6857

Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 6857
Study: 33668061

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 272

Group type: COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 272

Group type: COMPARATOR
Intervention: SABR
Number of subjects: 272
Study: 33668562

Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention (co-created lifestyle intervention with six interactive father-child sessions and an eHealth component, delivered over a 14-week period)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention
Number of subjects: 0